

**NATIONAL  
DRUG SURVEY  
2014 - 2016**

**Contents**





# CONTENTS

<b>The Core Expert Committee .....</b>	<b>11</b>
<b>Preface .....</b>	<b>15</b>
<b>Chapter 1: Background .....</b>	<b>19</b>
<b>Global Scenario.....</b>	21
<b>Concerns in India.....</b>	23
<b>Government Initiatives in India .....</b>	25
<b>Drug Quality Surveys in other parts of the world .....</b>	26
<b>References .....</b>	29
<b>Chapter 2: Objectives .....</b>	<b>31</b>
<b>Chapter 3: Unique Features of National Drug Survey .....</b>	<b>35</b>
<b>Chapter 4: Conceptualisation .....</b>	<b>43</b>
<b>Ethical and Legal Considerations.....</b>	46
<b>Chapter 5: Pilot Study .....</b>	<b>51</b>
<b>Scope.....</b>	53
<b>Objectives.....</b>	53
<b>Methodology .....</b>	53
Training .....	54
Sample Size.....	56
Sampling Methodology .....	56
<b>Major Observations of the Pilot Study .....</b>	57
General Observations .....	57
Anecdotal Experiences .....	57
Sourcing the Retail Outlets .....	57
Collection of Samples .....	57

Packaging of Samples .....	58
Documentation .....	58
Training .....	58
<b>Results of the Sample Collection.....</b>	<b>59</b>
<b>Results of the Laboratory Tests.....</b>	<b>60</b>
<b>Conclusion.....</b>	<b>61</b>
<b>Chapter 6: Design .....</b>	<b>63</b>
<b>Source.....</b>	<b>65</b>
<b>Population.....</b>	<b>66</b>
Molecules .....	66
Formulations .....	66
Quality of Drugs .....	67
Survey Objectives.....	67
Coverage Issues and Decisions.....	68
<b>Statistical Design .....</b>	<b>68</b>
Population Units .....	69
Sampling Scheme.....	69
First Stage of Sampling.....	70
Second Stage of Sampling .....	70
Third Stage of Sampling.....	70
Implementing the Sampling Scheme .....	70
<b>Estimation of Parameters .....</b>	<b>71</b>
Sample Size.....	73
<b>Sampling from Ports .....</b>	<b>76</b>
Procedure for Drawing Samples from Imports .....	78
<b>Summary .....</b>	<b>79</b>
<b>References .....</b>	<b>80</b>
<b>Chapter 7: AKS Software.....</b>	<b>81</b>
<b>About AKS Software .....</b>	<b>83</b>



<b>Development of the Drugs Survey – AKS Software .....</b>	<b>84</b>
<b>Phase I: Planning.....</b>	<b>85</b>
<b>Phase II: Preparation .....</b>	<b>90</b>
<b>Phase III: Software Validation and Operationalization .....</b>	<b>91</b>
Presentation and Offline Demonstration of the software at Drugs Consultative Committee (DCC) Meeting at Central Drugs Standard Control Organization, HQ .....	91
Field validation of AKS Software at Chennai Workshop .....	92
Pilot Study .....	94
Training for Trainers .....	95
Training for Trainees .....	96
AKS Software for main Drug Survey .....	98
<b>Phase IV: Maintenance .....</b>	<b>99</b>
<b>Phase V: Statistical Analysis of the Drugs Survey Data .....</b>	<b>99</b>
<b>References .....</b>	<b>100</b>
<b>Chapter 8: Training .....</b>	<b>101</b>
<b>Training Concept .....</b>	<b>103</b>
<b>Training Objectives .....</b>	<b>103</b>
<b>Training Purpose .....</b>	<b>103</b>
<b>Key Assumptions in Training.....</b>	<b>104</b>
<b>Roles and Responsibilities of State Drug Control Departments....</b>	<b>105</b>
<b>Roles and Responsibilities of Representatives of     Civil Society/Pharmacy Council of India .....</b>	<b>105</b>
<b>Cascade Methodology .....</b>	<b>106</b>
<b>Training Support .....</b>	<b>108</b>
<b>Training Rollout.....</b>	<b>108</b>
<b>Outcome .....</b>	<b>113</b>
<b>Chapter 9: Main Survey .....</b>	<b>115</b>
<b>Pre-Drug Sampling Preparation.....</b>	<b>117</b>

Identification and training of sample drawing team.....	117
Availability of physical resources .....	117
<b>Sampling Procedure .....</b>	<b>117</b>
Locating the Source.....	119
Drawing of samples from the Source, feeding the data of the Source & sample particulars in the Data Form...	121
Packing the samples and posting them along with the Data Form to NIB after feeding the particulars in the AKS software.....	131
<b>Receipt of Samples at NIB, Visual Inspection and Transport of Samples to Laboratories .....</b>	<b>135</b>
Receipt of Samples at NIB.....	135
Visual Inspection.....	135
Segregation of Samples .....	137
Transport of samples to drug testing laboratories.....	137
<b>Receipt of Samples, Testing and Reporting of Results by Laboratories.....</b>	<b>138</b>
Receipt.....	138
Test/Analysis Methods and Specifications .....	139
Reporting of Results .....	139
<b>Chapter 10: Survey Results and Analysis.....</b>	<b>141</b>
<b>Introduction .....</b>	<b>143</b>
Questions on Conduct of the Survey .....	144
Questions on Quality of Drugs .....	144
<b>Sampling .....</b>	<b>145</b>
Selection of Sources .....	145
Distributions of Samples.....	146
Selection of Formulations.....	148
Analysis of date expired samples.....	148
Batch Consistency .....	149
Hit Rates .....	150



<b>Retail Outlets</b> .....	150
Analysis of Part-A Data.....	152
Coverage of Outlets and Hit Rates .....	152
Analysis of Part-B Data.....	154
Distribution of Number of Samples in Retail Outlets .....	161
Inclusion Probabilities of Molecule IDs.....	162
Coverage of Dosage Forms .....	165
Analysis of Lab Data.....	167
<b>Government Sources</b> .....	176
Analysis of Part-A Data.....	176
Coverage of Outlets and Hit Rates .....	176
Distribution of Number of Samples in a Govt. Source .....	180
Analysis of Part- B Data of Government Sources.....	181
Coverage of Molecules .....	181
Dosage Forms .....	187
Expired Formulations .....	188
Lab Test Results and NSQ Proportion.....	190
<b>Ports</b> .....	198
<b>Analysis of Spurious Drugs</b> .....	203
<b>Summary</b> .....	206
Summary of Survey Aspects.....	206
Summary of Lab Test Results and Quality of Drugs .....	207
National Survey NSQ and Spurious Drugs Database.....	208
Retail Outlets.....	208
Government Sources.....	208
Ports.....	209
<b>Chapter 11: Summary &amp; Recommendations</b> .....	<b>211</b>
Introduction .....	213
Ministry of Health and Family Welfare .....	213

Findings of National Drug Survey .....	215
NSQ and Spurious Drugs Database .....	215
Retail Outlets.....	215
Government Supply Chain.....	215
Ports.....	216
<b>Recommendations .....</b>	<b>216</b>
Government .....	216
Drug Regulators .....	219
Government Drug Testing Laboratories.....	221
Drug Manufacturers .....	221
Drug Distributors and Retailers .....	222
Civil Society.....	223
Health Professionals .....	224
<b>Epilogue .....</b>	<b>225</b>
<b>Abbreviations .....</b>	<b>227</b>
<b>Glossary .....</b>	<b>233</b>
<b>ANNEXURES</b>	
<b>Annexure 1</b>	
Ministry’s In-principle Approval Letter to NIB for Undertaking Drug Survey .....	239
<b>Annexure 2</b>	
Ministry’s Approval Letter to NIB for Conduct of Drug Survey .....	243
<b>Annexure 3</b>	
References of 47 Global Drug Quality Surveys .....	247
<b>Annexure 4</b>	
State-wise Drug Survey Data .....	255
<b>Annexure 5</b>	
Test/Analysis Data of Drug Samples - Source wise .....	297
<b>NIB Resource Persons .....</b>	<b>455</b>